Buparlisib
Squamous Cell Lung Carcinoma
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
47 Active assets in the Squamous Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Qilu Hospital of Shandong University | Phase 4 | BBB |
Carboplatin zhang yi | Phase 3 | BBB |
Docetaxel Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Cyclophosphamide UNC Lineberger Comprehensive Cancer Center | Phase 3 | BB |
ETOPOSIDE Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Buparlisib is also rated in:
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →